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Purpose: To determine variations in cytokine levels of glaucoma patients treated either with
preservative-free latanoprost or preserved latanoprost, relative to healthy individuals.
Methods: Tear samples were collected from 39 healthy subjects, 20 glaucoma patients treated with
preserved latanoprost, and 20 patients treated with preservative-free latanoprost. A set of 27 in-
ﬂammatory cytokines was analyzed in each group, including interleukin (IL)-1b, IL-1ra, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-8, IL9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, ﬁbroblast growth factor (FGF)
basic, granulocyte colony stimulating factor (G-CSF), granulocyte monocyte colony stimulating factor
(GM-CSF), interferon (IFN)-g, interferon gamma-induced protein (IP)-10, monocyte chemo attractant
protein (MCP)-1MCAF, macrophage inﬂammatory protein (MIP)-1a, MIP-1b, platelet-derived growth
factor (PDGF)-BB, regulated on activation, normal T cell expressed and secreted (RANTES), tumor
necrosis factor (TNF)-a and vascular endothelial growth factor (VEGF). Cytokine concentrations were
obtained by the Bio-Plex Human Cytokine Immunoassay. Non-invasive tear breakup time (NI-TBUT),
tear meniscus height, corneal ﬂuorescein staining, conjunctival hyperemia and ocular surface
disease index (OSDI) were assessed in patients treated with preservative-free and preserved
latanoprost.
Results: The levels of IL-2, IL-5, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, FGF basic, PDGF-BB, and TNF-a were
signiﬁcantly higher in patients receiving preserved latanoprost, compared to normal controls (p < 0.05).
The expression of all the cytokines studied remained statistically invariable in patients receiving
preservative-free latanoprost, compared to healthy subjects (p > 0.05). Ocular surface parameters were
not signiﬁcantly different in both glaucoma groups, and no correlation between these clinical parameters
and cytokine levels was observed.
Conclusions: Treatment with preserved latanoprost has a direct impact on tear cytokine levels, whereas
this effect is not observed upon preservative-free latanoprost instillation.
© 2017 Elsevier Inc. All rights reserved.th factor; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte monocyte colony stimulating factor; IFN,
P, monocyte chemo attractant protein; MIP, macrophage inﬂammatory protein; PDGF, platelet-derived growth factor;
sed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; IOP, intraocular pressure; PGA,
; OSD, ocular surface disease; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; NI-TBUT, non-
ase Index.
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Glaucoma affects over 60 million people worldwide and is the
second leading cause of blindness [1]. Elevated intraocular pressure
(IOP) is the main risk factor for development of glaucoma. Thus, the
goal of the current standard of care is to lower IOP levels. Following
this rationale, different topical hypotensive compounds have
emerged, including prostaglandin analogues (PGAs), carbonic
anhydrase inhibitors, b-adrenergic receptor antagonists, a-2 se-
lective adrenergic agonists, and non-selective adrenergic agonists.
Remarkably, their high IOP-reducing efﬁcacy places PGAs as one of
the ﬁrst-line treatments for glaucoma [2].
In PGAs-based formulations, supplementation with pre-
servatives to protect from microbial contamination entails several
ocular side effects [3,4]. The presence of benzalkonium chloride
(BAK) in latanoprost, the most frequently prescribed PGA, is asso-
ciated with conjunctival hyperemia, superﬁcial punctate keratop-
athy, or squamous metaplasia [5e7]. Furthermore, long-term
exposure to BAK-preserved medications may cause or aggravate
pre-existing ocular surface diseases (OSDs), such as dry eye, ble-
pharitis, meibomian gland dysfunction, chronic conjunctival
inﬂammation, or corneal surface impairment [8,9]. These ocular
disorders result in eye irritation, blurred vision or tearing, and in a
general deterioration of patients' quality of life [10]. To circumvent
these detrimental effects, efforts have been made to develop
preservative-free formulations for the management of glaucoma.
Following this approach, preservative-free latanoprost was devel-
oped as a topical glaucoma treatment. Compared with its preserved
counterpart, preservative-free latanoprost showed equivalent efﬁ-
cacy in reducing IOP, was better tolerated, and reduced the number
of associated ocular adverse events, such as conjunctival hyperemia
[11e13]. However, the mechanisms behind these favorable effects
are not completely understood.
Inﬂammation is the key underlying mechanism fueling
preservative-associated OSDs. Hypotensive eye drops induce the
expression of several cytokines, including interleukins, interferon
(IFN)-g, and tumor necrosis factor (TNF)-a [8,14]. Therefore, cyto-
kines have become reliable biomarkers for the diagnosis, moni-
toring, and classiﬁcation of OSDs. Their increasing importance is
evidenced by the number of tools applied to detect cytokines in
tears, including proteomic techniques, enzyme-linked immuno-
sorbent assay (ELISA), membrane microarrays, and multiplex bead
assays [15].
In this study, we compared the cytokine proﬁle of patients
treated either with preservative-free latanoprost (Monoprost®;
Thea, Clermont-Ferrand, France) or preserved latanoprost (Xala-
tan®; Pﬁzer, New York, USA), by using multiplex bead technology.
We evaluated changes in the concentration of 27 inﬂammatory
cytokines in glaucoma patients, treated with or without pre-
servatives, relative to healthy patients. To the best of our knowl-
edge, this is the ﬁrst study comparing the impact in cytokine
concentration of long-term instillation with either preserved or
preservative-free eye drops.
2. Material and methods
2.1. Participants
This prospective, observational study was conducted at the
Hospital Clínico San Carlos (Madrid, Spain). A total of 79 subjects
were prospectively recruited between December 2015 and April
2016. Glaucoma patients were receiving either Monoprost or
Xalatan for periods ranging from 6 to 120 months. The study also
enrolled 39 healthy age- and sex-matched controls.
The study adhered to the tenets of the Declaration of HelsinkiPlease cite this article in press as: Martinez-de-la-Casa JM, et al., Tear cy
preserved latanoprost, The Ocular Surface (2017), http://dx.doi.org/10.10and the Spanish legislation, and was approved by the local Insti-
tutional Clinical Research Ethics Committee. Written legally-
binding informed consent was obtained from all participants
before recruitment.
Exclusion criteria included glaucoma surgery within the last six
months, secondary glaucoma (including congenital, traumatic,
steroid, uveitic, or angle closure), treatment with concomitant
topical medications (such as lubricant eye-drops), any ocular sur-
face disease that could have inﬂuenced treatment election, other
serious eye disease or syndrome, or any physical or mental problem
hindering the realization of tests or examinations required for the
study.
Each patient was examined andmedical history was recorded in
a single visit. The information collected included demographic data,
treatment duration, and the type (Monoprost or Xalatan) of eye
drops received.
2.2. Tear collection
Tear samples were collected using a sterile microcapillary tube
from a single eye of each individual. Samples were frozen at80 C
and stored until analysis. To avoid evaporation or degradation, the
elapsed time between collection and storage was kept below
15 min. Since tear volumes ranged from 2 to 15 mL, saline buffer
(Braun Mini-Plasco®) was added to each sample before storage to
reach 50 mL (the minimum volume for analysis).
2.3. Cytokine quantiﬁcation
Cytokine concentrations were determined in tear samples using
the Bio-Plex Pro Human Cytokine 27-Plex Immunoassay (Bio-Rad
Laboratories). This platform is based on ﬂuorescent magnetic beads
and allows the simultaneous detection of samples in 96-microwell
plates, requiring low sample volumes [16e18]. With this technol-
ogy, up to 27 relevant inﬂammatory cytokines could be detected in
a single run. The set of cytokines detected were: interleukin (IL)-1b,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL9, IL-10, IL-12 (p70), IL-13, IL-
15, IL-17, eotaxin, ﬁbroblast growth factor (FGF) basic, granulocyte
colony stimulating factor (G-CSF), granulocyte monocyte colony
stimulating factor (GM-CSF), interferon (IFN)-g, interferon gamma-
induced protein (IP)-10, monocyte chemo attractant protein (MCP)-
1MCAF, macrophage inﬂammatory protein (MIP)-1a, MIP-1b,
platelet-derived growth factor (PDGF)-BB, regulated on activation,
normal T cell expressed and secreted (RANTES), tumor necrosis
factor (TNF)-a and vascular endothelial growth factor (VEGF).
Brieﬂy, 50 mL of tear samples were dispensed into deﬁned wells
of the 96-microwell plate. Samples were simultaneously read on
the Luminex MAGPIX reader (Luminex Corporation, Austin TX
USA). Cytokine concentrations were derived by interpolating the
measured ﬂuorescence intensities to standard curves, and cor-
recting by the corresponding dilution factor employed to achieve
the minimum volume for analysis. Bio-Plex Manager™ software
was employed to calculate cytokine concentrations.
2.4. Ocular surface measurements
The ocular surface parameters evaluated included corneal
ﬂuorescein staining, non-invasive tear breakup time (NI-TBUT), tear
meniscus height, conjunctival hyperemia and ocular surface dis-
ease index (OSDI). These parameters were assessed at least 48 h
before or after tear sample acquisition.
NI-TBUT and conjunctival hyperemia were measured by the
Keratograph 5 (Oculus, Wetzlar, Germany), and the lower tear
meniscus height was evaluated by the Spectralis Fourier-Domain
OCT (Heidelberg Engineering GmbH, Germany) [19].tokine proﬁle of glaucoma patients treated with preservative-free or
16/j.jtos.2017.03.004
Table 2
Cytokine concentrations in Xalatan-treated and control subjects.
Cytokine Control Xalatan p-value
IL-1b 51.99 ± 44.38 73.74 ± 60.01 0.120
IL-1ra 18,120.10 ± 17,296.27 14,150.58 ± 10,067.61 0.359
IL-2 79.48 ± 67.76 130.22 ± 84.72 0.028*
IL-4 58.93 ± 40.28 75.10 ± 53.41 0.198
IL-5 150.56 ± 133.52 258.91 ± 221.34 0.024*
IL-6 161.79 ± 150.37 185.92 ± 131.44 0.546
IL-7 442.35 ± 343.28 631.08 ± 475.92 0.086
IL-8 573.88 ± 465.33 475.80 ± 314.45 0.402
IL-9 230.65 ± 168.14 339.96 ± 244.85 0.050
IL-10 243.01 ± 182.77 392.86 ± 295.55 0.019*
IL-12 (p70) 334.28 ± 222.28 505.92 ± 328.43 0.021*
IL-13 120.99 ± 95.26 193.62 ± 129.48 0.017*
IL-15 149.26 ± 107.10 228.37 ± 130.37 0.047*
IL-17 343.83 ± 332.85 634.36 ± 472.46 0.009*
Eotaxin 396.77 ± 251.72 512.45 ± 327.51 0.140
FGF basic 303.67 ± 215.90 547.02 ± 355.85 0.002*
G-CSF 621.68 ± 483.07 700.72 ± 489.66 0.560
GM-CSF 168.91 ± 124.44 227.03 ± 136.41 0.123
IFN-g 2034.27 ± 1331.88 2677.13 ± 1857.30 0.134
IP-10 25,632.69 ± 28,754.16 14,130.95 ± 15,142.54 0.102
MCP-1 (MCAF) 489.70 ± 304.50 633.31 ± 388.62 0.124
MIP-1a 54.92 ± 38.41 70.14 ± 44.04 0.176
PDGF-BB 126.17 ± 113.44 234.96 ± 201.35 0.010*
MIP-1b 174.03 ± 176.80 124.14 ± 77.96 0.249
RANTES 320.03 ± 218.74 394.26 ± 228.71 0.231
TNF-a 317.12 ± 263.14 602.44 ± 502.04 0.006
VEGF 476.41 ± 286.34 495.52 ± 282.81 0.808
Data are expressed as mean (pg/mL) ± SD.
Statistical signiﬁcance between groups was determined using Student's t-test.
*Indicates a statistically signiﬁcant difference (p < 0.05).
Abbreviations: IL¼ interleukin; FGF¼ ﬁbroblast growth factor; G-CSF¼ granulocyte
colony stimulating factor; GM-CSF ¼ granulocyte monocyte colony stimulating
factor; IFN ¼ interferon; IP ¼ interferon gamma-induced protein;
MCP1(MCAF) ¼ monocyte chemo attractant protein; MIP ¼ macrophage inﬂam-
matory protein; PDGF ¼ platelet-derived growth factor; RANTES ¼ regulated on
activation, normal T cell expressed and secreted; TNF ¼ tumor necrosis factor;
VEGF ¼ vascular endothelial growth factor; SD ¼ standard deviation.
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magniﬁcation. The cornea was stained using ﬂuorescein staining
(Minims-ﬂuorescein sodium 2.0%; Chauvin Pharmaceuticals Ltd.).
Corneal staining was graded using the 6-point Oxford scale (0 ¼ no
staining; 5 ¼ severe staining). Since all the patients evaluated
exhibited a maximum corneal staining score of 1, this variable was
subsequently graded as negative or positive (score 0 or 1,
respectively).
Global OSDI score was calculated for each participant from the
following equation: 12.5  [(sum of individual question scores)/
(number of questions answered)], which yields a global score
ranging from 0 to 100.
2.5. Statistical methods
Statistical analyses were performed using SAS software for
Windows, version 9.2. To evaluate differences between study
groups, quantitative variables were analyzed using the Student's t-
test for independent samples, whereas categorical variables were
compared using the Chi-square test. Spearman rank correlationwas
used to analyze the correlations between tear cytokine levels and
ocular surface parameters. The adjusted level was established by
Bonferroni test. p < 0.05 was the threshold to determine statisti-
cally signiﬁcant differences.
3. Results
3.1. Demographic characteristics of study groups
Demographic characteristics of the participants are listed in
Table 1. A total of 79 subjects (median age, 70 years; range, 29e88
years) participated in this study; 34 were males (43.0%) and 45
were females (57.0%). The study enrolled 40 glaucoma patients, and
39 individuals with no history of ocular disease were enrolled as
untreated controls. Among glaucoma patients, 20 were receiving
Monoprost and the other 20 Xalatan as topical anti-glaucoma
medication. Mean time of treatment did not statistically differ be-
tween the two groups (29.6 ± 27.2 months for Monoprost and
33.8 ± 26.5 months for Xalatan; p ¼ 0.619). The demographic var-
iables assessed were not signiﬁcantly different between groups
(p > 0.05).
3.2. Effects of Xalatan on tear cytokine levels
A set of 27 relevant inﬂammatory cytokines were analyzed in
Xalatan-treated and control tears. The absolute concentration of
each cytokine is presented in Table 2. Cytokine levels were sys-
tematically greater in patients receiving Xalatan, compared to
healthy participants (Fig. 1). Among all the cytokines evaluated,
there was a signiﬁcant increase (p < 0.05) in the levels of IL-2, IL-
5, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, FGF basic, PDGF-BB, and
TNF-a in Xalatan-treated versus control subjects. Remarkably,Table 1
Demographic characteristics of study participants.
Control Monoprost
Gender, N (%)
Male 16 (41%) 10 (50%)
Female 23 (59%) 10 (50%)
Total 39 (100%) 20 (100%)
Age (years), Mean ± SD 72.72 ± 8.67 70.35 ± 13.92
Data are expressed as number (percentage), or mean ± SD.
Abbreviations: N ¼ number of patients; SD ¼ standard deviation.
Statistical signiﬁcance between groups was determined using either the Student's t-test
Please cite this article in press as: Martinez-de-la-Casa JM, et al., Tear cy
preserved latanoprost, The Ocular Surface (2017), http://dx.doi.org/10.10PDGF-BB and TNF-a showed the highest increase in concentration
(1.9-fold) in patients treated with Xalatan, relative to normal
subjects.3.3. Effects of Monoprost on tear cytokine levels
Cytokine concentrations in Monoprost-treated and control tears
are given in Table 3. Levels of cytokines were highly coincident for
Monoprost and control groups (Fig. 1). Likewise, changes in cyto-
kine concentrations between patients receiving Monoprost and
healthy subjects failed to reach statistical signiﬁcance for all the 27
cytokines studied (p > 0.05). Remarkably, those cytokines with
signiﬁcantly increased levels in the previous comparison (Xalatan
versus control), remained statistically invariable when Monoprost-
treated patients were compared with healthy patients.Xalatan Total p-value
8 (40%) 34 (43%) 0.765
12 (60%) 45 (57%)
20 (100%) 79 (100%)
71.65 ± 9.93 71.85 ± 10.43 0.713
or the Chi-square test for continuous or categorical variables, respectively.
tokine proﬁle of glaucoma patients treated with preservative-free or
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Fig. 1. Bar graph showing cytokine concentrations in patients treated with Xalatan or Monoprost and in control subjects. The bar graph shows the concentration of each of
the 27 cytokines determined by the Bio-Plex Pro Human Cytokine 27-Plex Immunoassay: interleukin (IL); ﬁbroblast growth factor (FGF); granulocyte colony stimulating factor (G-
CSF); granulocyte monocyte colony stimulating factor (GM-CSF); interferon (IFN); interferon gamma-induced protein (IP); monocyte chemo attractant protein (MCP1(MCAF));
macrophage inﬂammatory protein (MIP); platelet-derived growth factor (PDGF); regulated on activation, normal T cell expressed and secreted (RANTES); tumor necrosis factor
(TNF); vascular endothelial growth factor (VEGF). Values are expressed as mean (pg/mL) ± standard deviation (SD).
J.M. Martinez-de-la-Casa et al. / The Ocular Surface xxx (2017) 1e743.4. Cytokine proﬁles and clinical parameters in Monoprost and
Xalatan groups
The comparison of Xalatan- and Monoprost-treated tearsPlease cite this article in press as: Martinez-de-la-Casa JM, et al., Tear cy
preserved latanoprost, The Ocular Surface (2017), http://dx.doi.org/10.10revealed that, except for IP-10, all the cytokines evaluated were
higher in the Xalatan group, with the levels of IL-2, IL-15, IL-17 and
TNF-a reaching statistical signiﬁcance (p < 0.05) (Table 4, Fig. 1).
Clinical parameters of ocular surface showed similar levels intokine proﬁle of glaucoma patients treated with preservative-free or
16/j.jtos.2017.03.004
Table 3
Cytokine concentrations in Monoprost-treated and control subjects.
Cytokine Control Monoprost p-value
IL-1b 53.10 ± 67.05 51.99 ± 44.38 0.939
IL-1ra 14,069.58 ± 10,054.80 18,120.10 ± 17,296.27 0.349
IL-2 68.69 ± 63.21 79.48 ± 67.76 0.592
IL-4 57.48 ± 54.07 58.93 ± 40.28 0.908
IL-5 181.62 ± 217.64 150.56 ± 133.52 0.503
IL-6 162.51 ± 171.08 161.79 ± 150.37 0.987
IL-7 488.20 ± 461.86 442.35 ± 343.28 0.668
IL-8 428.52 ± 289.48 573.88 ± 465.33 0.219
IL-9 272.26 ± 281.40 230.65 ± 168.14 0.492
IL-10 290.68 ± 351.42 243.01 ± 182.77 0.494
IL-12 (p70) 377.24 ± 443.19 334.28 ± 222.28 0.620
IL-13 138.74 ± 160.53 120.99 ± 95.26 0.596
IL-15 122.86 ± 76.12 149.26 ± 107.10 0.442
IL-17 295.49 ± 280.22 343.83 ± 332.85 0.604
Eotaxin 385.54 ± 352.04 396.77 ± 251.72 0.889
FGF basic 358.46 ± 435.10 303.67 ± 215.90 0.519
G-CSF 596.67 ± 722.30 621.68 ± 483.07 0.879
GM-CSF 162.25 ± 201.80 168.91 ± 124.44 0.882
IFN-g 1989.44 ± 1852.67 2034.27 ± 1331.88 0.916
IP-10 21,529.78 ± 20,541.95 25,632.69 ± 28,754.16 0.584
MCP-1 (MCAF) 560.90 ± 463.19 489.70 ± 304.50 0.481
MIP-1a 52.88 ± 55.96 54.92 ± 38.41 0.870
PDGF-BB 166.56 ± 248.59 126.17 ± 113.44 0.393
MIP-1b 107.33 ± 129.72 174.03 ± 176.80 0.173
RANTES 305.15 ± 308.74 320.03 ± 218.74 0.832
TNF-a 265.71 ± 263.83 317.12 ± 263.14 0.488
VEGF 464.41 ± 312.76 476.41 ± 286.34 0.883
Data are expressed as mean (pg/mL) ± SD.
Statistical signiﬁcance between groups was determined using the Student's t-test.
Abbreviations: IL¼ interleukin; FGF¼ ﬁbroblast growth factor; G-CSF¼ granulocyte
colony stimulating factor; GM-CSF ¼ granulocyte monocyte colony stimulating
factor; IFN ¼ interferon; IP ¼ interferon gamma-induced protein;
MCP1(MCAF) ¼ monocyte chemo attractant protein; MIP ¼ macrophage inﬂam-
matory protein; PDGF ¼ platelet-derived growth factor; RANTES ¼ regulated on
activation, normal T cell expressed and secreted; TNF ¼ tumor necrosis factor;
VEGF ¼ vascular endothelial growth factor; SD ¼ standard deviation.
Table 4
Cytokine concentrations in Monoprost- and Xalatan-treated subjects.
Cytokine Monoprost Xalatan p-value
IL-1b 53.10 ± 67.05 73.74 ± 60.01 0.312
IL-1ra 14,069.58 ± 10,054,80 14,150,58 ± 10,067.61 0.980
IL-2 68.69 ± 63.21 130.22 ± 84.72 0.022*
IL-4 57.48 ± 54.07 75.10 ± 53.41 0.307
IL-5 181.62 ± 217.64 258.91 ± 221.34 0.273
IL-6 162.51 ± 171.08 185.92 ± 131.44 0.637
IL-7 488.20 ± 461.86 631.08 ± 475.92 0.341
IL-8 428.52 ± 289.48 475.80 ± 314.45 0.629
IL-9 272.26 ± 281.40 339.96 ± 244.85 0.433
IL-10 290.68 ± 351.42 392.86 ± 295.55 0.326
IL-12 (p70) 377.24 ± 443.19 505.92 ± 328.43 0.303
IL-13 138.74 ± 160.53 193.62 ± 129.48 0.241
IL-15 122.86 ± 76.12 228.37 ± 130.37 0.016*
IL-17 295.49 ± 280.22 634.36 ± 472.46 0.014*
Eotaxin 385.54 ± 352.04 512.45 ± 327.51 0.245
FGF basic 358.46 ± 435.10 547.02 ± 355.85 0.142
G-CSF 596.67 ± 722.30 700.72 ± 489.66 0.603
GM-CSF 162.25 ± 201.80 227.03 ± 136.41 0.267
IFN-g 1989.44 ± 1852.67 2677.13 ± 1857.30 0.248
IP-10 21,529.78 ± 20,541.95 14,130.95 ± 15,142.54 0.207
MCP-1 (MCAF) 560.0 ± 463.19 633.31 ± 388.62 0.595
MIP-1a 52.88 ± 55.96 70.14 ± 44.04 0.285
PDGF-BB 166.56 ± 248.59 234.96 ± 201.35 0.345
MIP-1b 107.33 ± 129.72 124.14 ± 77.96 0.636
RANTES 305.15 ± 308.74 394.26 ± 228.71 0.306
TNF-a 265.71 ± 263.83 602.44 ± 502.04 0.013*
VEGF 464.41 ± 312.76 495.52 ± 282.81 0.743
Data are expressed as mean (pg/mL) ± SD.
Statistical signiﬁcance between groups was determined using the Student's t-test.
*Indicates a statistically signiﬁcant difference (p < 0.05).
Abbreviations: IL¼ interleukin; FGF¼ ﬁbroblast growth factor; G-CSF¼ granulocyte
colony stimulating factor; GM-CSF ¼ granulocyte monocyte colony stimulating
factor; IFN ¼ interferon; IP ¼ interferon gamma-induced protein;
MCP1(MCAF) ¼ monocyte chemo attractant protein; MIP ¼ macrophage inﬂam-
matory protein; PDGF ¼ platelet-derived growth factor; RANTES ¼ regulated on
activation, normal T cell expressed and secreted; TNF ¼ tumor necrosis factor;
VEGF ¼ vascular endothelial growth factor; SD ¼ standard deviation.
Table 5
Ocular surface parameters in Monoprost- and Xalatan-treated patients.
Monoprost Xalatan p-value
OSDI 11.220 ± 9.799 6.439 ± 7.052 0.121
Conjunctival Hyperemia 1.706 ± 0.522 1.400 ± 0.473 0.088
Tear Meniscus Height 324.000 ± 108.312 333.059 ± 104.711 0.809
NI-TBUT 8.836 ± 4.73,136 11.365 ± 6.045 0.189
Statistical signiﬁcance between groups was determined using either the Student's t-
test or the Chi-square test for continuous or categorical variables, respectively.
Abbreviations: OSDI ¼ ocular surface disease index; NI-TBUT ¼ non-invasive tear
breakup time.
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height, OSDI, NI-TBUT, and conjunctival hyperemia were statisti-
cally equivalent in Monoprost- and Xalatan-treated patients
(p> 0.05) (Table 5). Corneal ﬂuorescein staining and the presence of
epitheliopathy were not signiﬁcantly different between Monoprost
and Xalatan groups (p ¼ 0.491).
No signiﬁcant correlationwas observed between cytokine levels
and clinical parameters of ocular surface disease (OSDI, NI-TBUT,
conjunctival hyperemia, and tear meniscus height), when
analyzing those cytokines with signiﬁcantly different levels in
Monoprost and Xalatan groups (IL-2, IL-15, IL-17 and TNF-a).4. Discussion
Due to the chronic nature of glaucoma, many glaucomatous
patients require lifetime treatment. The current goal of anti-
glaucoma therapy is to lower IOP without compromising patients'
quality of life [10,20]. The use of PGAs as topical medication entails
several adverse events, which often derive from the presence of
preservatives in these ophthalmic preparations [21,22]. Adverse
events include inﬂammation or corneal impairment, among other
symptoms of discomfort, and can result in treatment discontinua-
tion [23e25]. In this regard, there is increasing concern about the
risks associated with the use of preservatives in anti-glaucoma
medications.
For this reason, developing new anti-glaucoma formulations
without preservatives appears to be a successful therapeutic
avenue for the management of glaucoma. Different preservative-
free PGAs are currently available that are no less effective inPlease cite this article in press as: Martinez-de-la-Casa JM, et al., Tear cy
preserved latanoprost, The Ocular Surface (2017), http://dx.doi.org/10.10reducing IOP than their preserved counterparts [26e28]. Further-
more, switching studies revealed that changing from preserved to
preservative-free medications signiﬁcantly improved signs and
symptoms related to OSDs [29,30].
Among PGAs, we focused on latanoprost, the most frequently
prescribed formulation, because of its high tolerability and the
lesser number of side effects associated with its use [7]. Despite its
potency, various adverse events have been associated with the
presence of BAK in latanoprost formulation [5e7]. Preservative-free
latanoprost (Monoprost) was therefore conceived to maintain the
drug potency of latanoprost while reducing the associated adverse
events.
A variety of studies support the advantages of Monoprost as
topical anti-glaucoma medication. In an in vivo study, Pauly and
colleagues revealed that epithelial cell viability was higher after
treatment with preservative-free latanoprost compared totokine proﬁle of glaucoma patients treated with preservative-free or
16/j.jtos.2017.03.004
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national trial demonstrated equivalent efﬁcacy between preserved
and preservative-free latanoprost in reducing IOP levels [12]. A
meta-analysis of randomized clinical trials conﬁrmed that
preservative-free latanoprost presented equivalent safety and
reduced adverse events, such as conjunctival hyperemia, compared
to preserved latanoprost [31]. A phase 2 study reported no differ-
ences between latanoprost with or without preservative, in terms
of safety and patient tolerance [32]. Additionally, commercializa-
tion in single-dose format ensures Monoprost sterility.
Several studies have revealed important differences between
preserved and preservative-free latanoprost, but none has directly
compared their impact on tear cytokine levels. Inﬂammation is a
key cause and effect of the onset and progression of OSDs, which
can be reliably monitored by measuring cytokine levels. In this
study, we compared differences in cytokine concentrations pro-
moted either by Monoprost or Xalatan in glaucoma patients. We
observed that treatment with Xalatan resulted in great variations of
cytokine levels in tears. However, and interestingly, upon treatment
with Monoprost, we only observed mild changes that did not reach
statistical signiﬁcance.
We simultaneously determined the concentration of 27 cyto-
kines employingmultiplex technology, thus eliminating inter-assay
variability. The cytokine proﬁle of patients treated with Xalatan
revealed a signiﬁcant increase in IL-2, IL-5, IL-10, IL-12 (p70), IL-13,
IL-15, IL-17, FGF basic, PDFG-BB, and TNF-a. Among them, PDFG-BB
and TNF-a showed the highest increase in concentration (1.9-fold)
in patients treated with Xalatan, whereas their expression was
statistically unchanged in patients treated with Monoprost. TNF-a
is a pleiotropic protein eliciting different cellular responses, such as
apoptotic cell death or inﬂammation [33]. Consistently, both
apoptosis and inﬂammation participate in ocular adverse events
associated with the use of preservatives in ophthalmic prepara-
tions. Indeed, BAK is able to interact with cell death receptors,
inducing apoptosis and inﬂammation [34,35]. This fact, together
with the elevated levels of TNF-a in patients treated with Xalatan,
suggests that apoptosis could also play a role in these associated
side effects. In addition to playing this role, TNF-a is a recognized
marker of dry eye disease [18,36]. In line with this, growth factors
such as PDGF-BB and FGF basic play a critical role in the mainte-
nance of corneal function and imbalances in their expression are
found in different ocular pathologies [37,38]. In addition, IL-17 (the
IL presenting the highest increase) is also associated with the
severity of different OSDs, such as uveitis, scleritis and dry eye
disease [39e41]. Overall, patients treated with Xalatan presented
an increased expression of different OSD markers, which could
indicate that they are more prone to suffer or exacerbate these
ophthalmic pathologies.
Nevertheless, other relevant markers of OSDs, such as IL-b1 or
IL-6, are not differentially expressed in patients treated with
Xalatan [42]. This apparent discrepancy could be explained
considering that early and late inﬂammatory responses greatly
differ in their cytokine proﬁle. In this regard, this study was con-
ducted in individuals already under treatment for long-term pe-
riods (ranging from 6 to 120 months). This fact represents an
important strength of our study, since it reﬂects the actual context
of patients chronically exposed to anti-glaucoma treatments. In
contrast, clinical trials are usually performed according to short-
term schedules, thus underestimating potential long-term effects.
Unexpectedly, no relevant differences in ocular surface measure-
ments (corneal staining, conjunctival hyperemia, NI-TBUT, and tear
meniscus height) were observed between Xalatan- andMonoprost-
treated patients. In addition, cytokine levels and these ocular sur-
face parameters were not statistically correlated in either the
Xalatan or the Monoprost groups. Thus, although the presence ofPlease cite this article in press as: Martinez-de-la-Casa JM, et al., Tear cy
preserved latanoprost, The Ocular Surface (2017), http://dx.doi.org/10.10BAK is not apparently inﬂuencing these ocular surface markers, it
could be impacting other clinical outcomes, such as the success of
posterior glaucoma surgery. The lack of correlation indicates that
the inﬂammatory status achieved after long-term treatment with
either Monoprost or Xalatan is not directly translated in detectable
differences by exploratory procedures. This fact could be explained
considering the wide variation of treatment durations that could
compensate potential differences in clinical measurements be-
tween both groups. This idea is in accordance with previous studies
in which transition from latanoprost to BAK-free tavoprost showed
that hyperemia was not signiﬁcantly altered at 1 month, but it was
signiﬁcantly decreased after 3e12 months of treatment [43].
Hence, it would be interesting to unveil the inﬂammatory proﬁle of
patients as a function of treatment duration, to distinguish between
acute and chronic adverse events derived from the use of pre-
servatives, and to establish its potential correlation with ocular
surface markers.
A limitation of this study is that basal levels of cytokines were
not determined before treatment initiation. However, since patient
selection was not based on clinical characteristics or previous
treatment intolerances, we can assume that cytokine levels were
balanced between both groups. Further studies should be con-
ducted using a crossover design switching from preserved to
preservative-free latanoprost, and vice versa. By quantifying cyto-
kine levels before and after each treatment course, we could rule
out any baseline effect.
Taken together, the results of this study support previous re-
ports of the beneﬁcial effects of Monoprost in patients, and high-
lights the importance of assessing the cytokine proﬁle to
characterize inﬂammatory effects of topical medications.
5. Conclusions
This study compared the cytokine proﬁle of patients treated
with preservative-free or preserved latanoprost. The lack of
inﬂammation associated with preservative-free latanoprost treat-
ment is likely responsible for its signiﬁcant reduction of adverse
events. These ﬁndings may have special relevance for patients
receiving long-term treatment, and with OSDs.
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